-
Publication Venue For
-
Patterns of de-novo metastasis and breast cancer-specific mortality by race and molecular subtype in the SEER population-based dataset..
186:509-518.
2021
-
Time to surgery among women treated with neoadjuvant systemic therapy and upfront surgery for breast cancer..
186:535-550.
2021
-
Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience..
184:733-741.
2020
-
Factors associated with falls in older women with breast cancer: the use of a brief geriatric screening tool in clinic..
184:445-457.
2020
-
Overall health at diagnosis predicts the risk of complications within the first year after breast cancer diagnosis..
182:439-449.
2020
-
G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer..
180:635-646.
2020
-
Correction to: Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy..
179:769.
2020
-
Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients..
180:207-217.
2020
-
Bimodal age distribution at diagnosis in breast cancer persists across molecular and genomic classifications..
179:185-195.
2020
-
Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy..
179:67-77.
2020
-
Syndecan-1 facilitates breast cancer metastasis to the brain..
178:35-49.
2019
-
Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases..
176:321-328.
2019
-
Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial)..
176:303-310.
2019
-
Shared-patient physician networks and their impact on the uptake of genomic testing in breast cancer..
176:445-451.
2019
-
Adipose stem cell crosstalk with chemo-residual breast cancer cells: implications for tumor recurrence..
174:413-422.
2019
-
Metabolic syndrome and risk of breast cancer mortality by menopause, obesity, and subtype..
174:209-218.
2019
-
Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set..
173:455-463.
2019
-
Obesity and mortality after locoregional breast cancer diagnosis..
172:647-657.
2018
-
Intra-tumor molecular heterogeneity in breast cancer: definitions of measures and association with distant recurrence-free survival..
172:123-132.
2018
-
Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study..
171:325-334.
2018
-
Total and out-of-pocket expenditures among women with metastatic breast cancer in low-deductible versus high-deductible health plans..
171:449-459.
2018
-
Impact of high-deductible insurance on adjuvant hormonal therapy use in breast cancer..
171:235-242.
2018
-
Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer..
171:111-120.
2018
-
Understanding racial/ethnic differences in breast cancer-related physical well-being: the role of patient-provider interactions..
170:593-603.
2018
-
Lymphedema, musculoskeletal events and arm function in older patients receiving adjuvant chemotherapy for breast cancer (Alliance A171302)..
166:793-808.
2017
-
Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer..
166:241-247.
2017
-
Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance)..
165:677-686.
2017
-
Breast cancer oral anti-cancer medication adherence: a systematic review of psychosocial motivators and barriers..
165:247-260.
2017
-
Erratum to: Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications..
164:745.
2017
-
Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications..
164:263-284.
2017
-
Early cardiac perfusion defects after left-sided radiation therapy for breast cancer: is there a volume response?.
164:253-262.
2017
-
Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance)..
164:107-117.
2017
-
Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503)..
163:391-398.
2017
-
Impact of self-reported data on the acquisition of multi-generational family history and lifestyle factors among women seen in a high-risk breast screening program: a focus on modifiable risk factors and genetic referral..
162:275-282.
2017
-
Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset..
162:1-10.
2017
-
Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511)..
161:363-373.
2017
-
Erratum to: Racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer..
160:385.
2016
-
Understanding racial differences in health-related quality of life in a population-based cohort of breast cancer survivors..
159:535-543.
2016
-
Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion..
158:441-454.
2016
-
Racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer..
158:333-340.
2016
-
Racial disparities in individual breast cancer outcomes by hormone-receptor subtype, area-level socio-economic status and healthcare resources..
157:575-586.
2016
-
Validation of an oligo-gene signature for the prognostic stratification of ductal carcinoma in situ (DCIS)..
157:447-459.
2016
-
Investigating racial disparities in use of NK1 receptor antagonists to prevent chemotherapy-induced nausea and vomiting among women with breast cancer..
156:351-359.
2016
-
Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer..
154:563-571.
2015
-
Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor..
154:287-297.
2015
-
Breast cancer survival in African-American women by hormone receptor subtypes..
153:211-218.
2015
-
Racial variation in adjuvant chemotherapy initiation among breast cancer patients receiving oncotype DX testing..
153:191-200.
2015
-
Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer..
152:347-356.
2015
-
Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02)..
152:77-85.
2015
-
Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial)..
151:589-596.
2015
-
Comparison of breast cancer risk in women with and without systemic lupus erythematosus in a Medicare population..
151:465-474.
2015
-
A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007..
148:99-106.
2014
-
Non-steroidal anti-inflammatory drug use, hormone receptor status, and breast cancer-specific mortality in the Carolina Breast Cancer Study..
147:415-421.
2014
-
TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases..
146:557-566.
2014
-
Breast cancer and aging: results of the U13 conference breast cancer panel..
146:1-6.
2014
-
The influence of diabetes severity on receipt of guideline-concordant treatment for breast cancer..
146:199-209.
2014
-
Long-term risk of medical conditions associated with breast cancer treatment..
145:233-243.
2014
-
Utility of 3-dimensional echocardiography, global longitudinal strain, and exercise stress echocardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy..
143:531-539.
2014
-
Ductal carcinoma in situ: knowledge of associated risks and prognosis among Latina and non-Latina white women..
141:261-268.
2013
-
A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting..
139:863-872.
2013
-
Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907..
139:607-616.
2013
-
FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast..
139:381-390.
2013
-
Prevalence and impact of correlative science in breast cancer phase II trials..
139:845-850.
2013
-
The influence of adjuvant therapy on cardiorespiratory fitness in early-stage breast cancer seven years after diagnosis: the Cooper Center Longitudinal Study..
138:909-916.
2013
-
A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer..
137:471-482.
2013
-
Impact of breast cancer on anti-mullerian hormone levels in young women..
137:571-577.
2013
-
Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism..
137:359-371.
2013
-
Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer..
136:35-43.
2012
-
The Piper Fatigue Scale-12 (PFS-12): psychometric findings and item reduction in a cohort of breast cancer survivors..
136:9-20.
2012
-
Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer..
134:371-378.
2012
-
Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice..
133:301-310.
2012
-
Gamma-ray-induced mutagen sensitivity and risk of sporadic breast cancer in young women: a case-control study..
132:1147-1155.
2012
-
Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways..
132:487-498.
2012
-
ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells..
132:109-119.
2012
-
Effect of primary prophylactic G-CSF use on systemic therapy administration for elderly breast cancer patients..
130:255-266.
2011
-
Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger..
130:587-597.
2011
-
Sleep duration change across breast cancer survivorship: associations with symptoms and health-related quality of life..
130:243-254.
2011
-
What can we learn from the age- and race/ethnicity- specific rates of inflammatory breast carcinoma?.
130:691-697.
2011
-
The effect of system-level access factors on receipt of reconstruction among Latina and white women with DCIS..
129:909-917.
2011
-
Surgery of the primary tumor does not improve survival in stage IV breast cancer..
129:459-465.
2011
-
Characterizing the impact of 25 years of DCIS treatment..
129:165-173.
2011
-
Breast cancer as heterogeneous disease: contributing factors and carcinogenesis mechanisms..
128:483-493.
2011
-
Chemotherapy characteristics are important predictors of primary prophylactic CSF administration in older patients with breast cancer..
127:511-520.
2011
-
The role of polymorphisms in circadian pathway genes in breast tumorigenesis..
127:531-540.
2011
-
Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer..
126:101-108.
2011
-
Individual responses to chemotherapy-induced oxidative stress..
125:583-589.
2011
-
Discovery and verification of protein differences between Er positive/Her2/neu negative breast tumor tissue and matched adjacent normal breast tissue..
124:297-305.
2010
-
Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis..
124:441-451.
2010
-
Fertility drugs and the risk of breast cancer: a meta-analysis and review..
124:13-26.
2010
-
Adoptively transferred ex vivo expanded gammadelta-T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer..
122:135-144.
2010
-
Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancer..
122:177-179.
2010
-
The functional promoter polymorphism (-842G>C) in the PIN1 gene is associated with decreased risk of breast cancer in non-Hispanic white women 55 years and younger..
122:243-249.
2010
-
Reliable data on 5- and 10-year survival provide accurate estimates of 15-year survival in estrogen receptor-positive early-stage breast cancer..
121:771-776.
2010
-
A phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer..
120:111-118.
2010
-
Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer..
119:137-144.
2010
-
Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care..
118:635-643.
2009
-
Reporting of race and ethnicity in breast cancer research: room for improvement..
118:511-517.
2009
-
Autocrine semaphorin3A stimulates alpha2 beta1 integrin expression/function in breast tumor cells..
118:197-205.
2009
-
The impact of sharing results of a randomized breast cancer clinical trial with study participants..
115:123-129.
2009
-
Analysis of dermatologic events in patients with cancer treated with lapatinib..
114:485-493.
2009
-
Association of genetic polymorphisms of ER-alpha and the estradiol-synthesizing enzyme genes CYP17 and CYP19 with breast cancer risk in Chinese women..
114:327-338.
2009
-
Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944)..
113:479-490.
2009
-
Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue repository of the Surveillance, Epidemiology, and End Results (SEER) program..
113:189-196.
2009
-
Are all aromatase inhibitors alike?.
112 Suppl 1:35-43.
2008
-
Genetic variants in the H2AFX promoter region are associated with risk of sporadic breast cancer in non-Hispanic white women aged .
110:357-366.
2008
-
EZH2 regulates the transcription of estrogen-responsive genes through association with REA, an estrogen receptor corepressor..
107:235-242.
2008
-
Axillary lymph node dissection in node-positive breast cancer: are ten nodes adequate and when is enough, enough?
2020
-
Breast cancer tumor histopathology, stage at presentation, and treatment in the extremes of age.
2020